Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05226767
Other study ID # NLC-V-01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 30, 2021
Est. completion date January 20, 2022

Study information

Verified date February 2022
Source Todos Medical, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and efficacy of NLC-V in patients diagnosed with COVID-19.


Description:

Herbal remedies and purified natural products provide a rich resource for the development of new antiviral drugs. The detection of antiviral mechanisms in these natural substances sheds light on where they interact with the viral life cycle, such as penetration, replication, assembly and release of the virus, as well as on tuning to specific host-virus interactions. CoV is a virus that belongs to the corona virus family. The CoV virus family causes infections in the upper respiratory tract and gastrointestinal tract in mammals and birds. In humans, it mainly causes colds, but complications can also occur, such as pneumonia and severe acute respiratory syndrome. Corona virus with the known acute respiratory syndrome caused a global threat with high mortality in 2003, and again in 2019 and 2020. The plant family of lithosperm, have been used in traditional Chinese medicine for the treatment of external wounds, burns or dermatitis for centuries. Studies conducted over the past 30 years have shown that there is a scientific basis and pharmacological properties. The active ingredients that were successfully extracted from the plant were found to be strong inhibitors of the enzyme family found in corona virus polypropylene 3C. Aim of the study: This study was designed to evaluate the efficacy of NLC-V in patients diagnosed with COVID-19. Details of the research and clinical follow-up phases: A total of 66 adult patients with a certified diagnosis of SARS-CoV-2 virus infection, who are hospitalized due to the infection, will be recruited. NLC-V study therapy is given in oral capsules. Each NLC-V capsule contains 100 mg of active ingredients in a special formulation. Patients will be randomly assigned a 1: 1 ratio to receive NLC-V or placebo, which are additionally given.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date January 20, 2022
Est. primary completion date November 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men and Women aged 18 (inclusive) and above. 2. Confirmed SARS-CoV-2 infection by RT-PCR If confirmed >5 days before the randomization, another test will be taken on day 1. 3. Hospitalized COVID-19 patient in stable moderate condition to upper scale of severe condition (i.e., not requiring full respiratory assessment). 4. Oxygenation < 96% on room air. 5. Subjects must be under observation or admitted to a controlled facility or hospital due to lung infection / respiratory infection only (home quarantine is not sufficient). - Exclusion Criteria: 1. Tube feeding or parenteral nutrition. 2. Respiratory decompensation requiring mechanical ventilation. 3. Pregnant or lactating women. 4. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints (for examples social condition other non-related medical illness). 5. Known to have severe allergic reactions to one of the study drug components. 6. Active tuberculosis (TB) infection. 7. Subjects diagnosed to suffer from concomitant active infection: bacterial, fungal, viral, or other infection cause besides COVID-19. 8. In the opinion of the investigator, progression to death is imminent and inevitable within the next 24-36 hours, irrespective of the provision of treatments. 9. Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months (steroids are permitted). 10. Participating in other drug clinical trial. 11. Estimated glomerular filtration rate (eGFR) < 30 mL/min (including patients receiving hemodialysis or hemofiltration). 12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal (ULN) detected within 24 hours of screening (according to local laboratory reference ranges). 13. Absolute neutrophil count (ANC) < 1000/uL at screening. 14. Platelet count < 50,000/uL at screening. 15. Body weight < 40 kg or >120 kg. 16. Treatment with other investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
NLC-V
NLC-V

Locations

Country Name City State
Israel Shaare Zedek Hospital Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Todos Medical, Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time relapsed from hospitalization (1st day) until hospital discharge in patients receiving NLC-V treatment. Time relapsed from hospitalization (1st day) until hospital discharge in patients receiving NLC-V treatment.
Primary Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 maintained for 24 hours, in the treatment group (NLC-V) compared to the control group. Time to clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of </= 2 maintained for 24 hours, in the treatment group (NLC-V) compared to the control group.
Secondary Rate of change of measured parameters. Time relapsed from hospitalization (1st day) until hospital discharge
Secondary Rate of change in vital signs (blood pressure, heart rate, respiratory rate, saturation, body temperature). Time relapsed from hospitalization (1st day) until hospital discharge
Secondary Time from the 1st day of receiving NLC-V treatment to negative test result by RT-PCR for COVID-19. Time relapsed from hospitalization (1st day) until hospital discharge
Secondary COVID-19 - related death in the treatment group (NLC-V) compared to the control group. Time relapsed from hospitalization (1st day) until hospital discharge
Secondary Incidence of deterioration and need to mechanical ventilation in both treatment group (NLC-V) and control group. Time relapsed from hospitalization (1st day) until hospital discharge
Secondary Incidence and duration of time on supplemental oxygen in both treatment group (NLC-V) and control group. Time relapsed from hospitalization (1st day) until hospital discharge
Secondary Sensitivity and specificity of NLC's COVID-19 diagnostic test Time relapsed from hospitalization (1st day) until hospital discharge
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure